Common stock, shares authorized (in shares)

  
 

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  |  |  |  |  |  |  |  |  |  |  |
| Cigna CorporationConsolidated Balance Sheets |
|  | Unaudited |
|  | As of September 30, |  | As of December 31, |
|  |  |
| (In millions) | 2022 |  | 2021 |
| Assets |  |  |  |
| Cash and cash equivalents | $ | 7,079  |  |  | $ | 5,081  |  |
| Investments | 783  |  |  | 920  |  |
| Accounts receivable, net | 17,275  |  |  | 15,071  |  |
| Inventories | 4,017  |  |  | 3,722  |  |
| Other current assets | 1,016  |  |  | 1,283  |  |
| Assets of businesses held for sale | —  |  |  | 10,057  |  |
| Total current assets | 30,170  |  |  | 36,134  |  |
| Long-term investments | 16,273  |  |  | 18,438  |  |
| Reinsurance recoverables | 4,826  |  |  | 4,970  |  |
| Deferred policy acquisition costs | 764  |  |  | 677  |  |
| Property and equipment | 3,744  |  |  | 3,692  |  |
| Goodwill | 45,807  |  |  | 45,811  |  |
| Other intangible assets | 32,885  |  |  | 34,102  |  |
| Other assets | 2,480  |  |  | 2,728  |  |
| Separate account assets | 7,260  |  |  | 8,337  |  |
| TOTAL ASSETS | $ | 144,209  |  |  | $ | 154,889  |  |
| Liabilities |  |  |  |
| Current insurance and contractholder liabilities | $ | 6,095  |  |  | $ | 5,318  |  |
| Pharmacy and other service costs payable | 16,676  |  |  | 15,309  |  |
| Accounts payable | 6,870  |  |  | 6,655  |  |
| Accrued expenses and other liabilities | 7,986  |  |  | 7,322  |  |
| Short-term debt | 3,488  |  |  | 2,545  |  |
| Liabilities of businesses held for sale | —  |  |  | 6,423  |  |
| Total current liabilities | 41,115  |  |  | 43,572  |  |
| Non-current insurance and contractholder liabilities | 11,655  |  |  | 12,563  |  |
| Deferred tax liabilities, net | 7,777  |  |  | 8,346  |  |
| Other non-current liabilities | 3,179  |  |  | 3,762  |  |
| Long-term debt | 28,090  |  |  | 31,125  |  |
| Separate account liabilities | 7,260  |  |  | 8,337  |  |
| TOTAL LIABILITIES | 99,076  |  |  | 107,705  |  |
| Contingencies — Note 18 |  |  |  |
| Redeemable noncontrolling interests | 50  |  |  | 54  |  |
| Shareholders' equity |  |  |  |
| Common stock (1) | 4  |  |  | 4  |  |
| Additional paid-in capital | 29,395  |  |  | 29,574  |  |
| Accumulated other comprehensive loss | (2,009) |  |  | (884) |  |
| Retained earnings | 37,041  |  |  | 32,593  |  |
| Less: Treasury stock, at cost | (19,390) |  |  | (14,175) |  |
| TOTAL SHAREHOLDERS' EQUITY | 45,041  |  |  | 47,112  |  |
| Other noncontrolling interests | 42  |  |  | 18  |  |
| Total equity | 45,083  |  |  | 47,130  |  |
| Total liabilities and equity | $ | 144,209  |  |  | $ | 154,889  |  |

(1) Par value per share, $0.01; shares issued, 397 million as of September 30, 2022 and 394 million as of December 31, 2021; authorized shares, 600 million.The accompanying Notes to the Consolidated Financial Statements (unaudited) are an integral part of these statements.5
